applications deemed ''Invalid'' by the Grants.gov Web site Portal will not be transferred to the OPHS eGrants system, and OPHS has no responsibility for any application that is not validated and transferred to OPHS from the Grants.gov Website Portal. Grants.gov will notify the applicant regarding the application validation status. Once the application is successfully validated by the Grants.gov Website Portal, applicants should immediately mail all required hard copy materials to the OPHS Office of Grants Management to be received by the deadlines specified above. It is critical that the applicant clearly identify the Organization name and Grants.gov Application Receipt Number on all hard copy materials.

Once the application is validated by Grants.gov, it will be electronically transferred to the OPHS eGrants system for processing. Upon receipt of both the electronic application from the Grants.gov Website Portal, and the required hardcopy mail-in items, applicants will receive notification via mail from the OPHS Office of Grants Management confirming the receipt of the application submitted using the Grants.gov Web site Portal.

Applicants are encouraged to initiate electronic applications via the Grants.gov Website Portal early in the application development process, and to submit early on the due date or before. This will aid in addressing any problems with submissions prior to the application deadline.

Applicants should contact Grants.gov regarding any questions or concerns regarding the electronic application process conducted through the Grants.gov Website Portal.

Mailed or Hand-Delivered Hard Copy Applications

Applications submitted in hard copy (via mail or hand-delivered) are required to submit an original and two copies of the application. The original application must be signed by an individual authorized to act for the applicant agency or organization and to assume for the organization the obligations imposed by the terms and conditions of the grant award.

Mailed or hand-delivered applications will be considered as meeting the deadline if they are received by the OPHS Office of Grant Management, on or before 5 p.m. Eastern Time on April 4, 2005. The application deadline date requirement specified in this announcement supersedes the instructions in the OPHS–1. Applications that do not meet the deadline will be returned to the applicant unread.

ADDRESSES: Applications mailed or hand-delivered must be sent to the OPHS Office of Grants Management, 1101 Wootton Parkway, Suite 550, Rockville, Maryland, 20852. For further information contact 301–594–0758.

FOR FURTHER INFORMATION CONTACT: OAPP at 301–594–4004 or *oapp@osophs.dhhs.gov.*

Dated: March 14, 2005.

Alma L. Golden,

Deputy Assistant Secretary for Population Affairs.

[FR Doc. 05–6272 Filed 3–29–05; 8:45 am]

BILLING CODE 4150–30–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Preventing Maternal and Neonatal Bacterial Infections in Developing Settings With a High Prevalence of HIV: Assessment of the Disease Burden and Evaluation of an Affordable Intervention in Soweto, South Africa; Notice of Intent To Fund Single Eligibility Award

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2005 funds for a cooperative agreement program to conduct a clinical trial to evaluate the efficacy of chlorhexidine vaginal wipes during labor at preventing perinatal and maternal post-partum sepsis in an African setting with a high prevalence of maternal HIV infection. In conjunction with this trial, risk factors for serious neonatal and maternal peripartum infections will be evaluated, with an emphasis on the impact of maternal HIV infection on these outcomes. Prospective maternal and neonatal infections surveillance will also be established to characterize the burden of disease. The Catalog of Federal Domestic Assistance number for this program is 93.283.

B. Eligible Applicant

Assistance will be provided only to the Respiratory and Meningeal Pathogens Unit of the Medical Research Council of South Africa. No other applications are solicited.

The Respiratory and Meningeal Pathogens Unit is the only institution that possesses the requisite scientific and technical expertise, the infrastructure capacity and experience and collaborative relationships necessary to conduct the described research topics and to ensure that all aspects of this agreement can be fulfilled. The Unit has already been a single eligibility recipient of a cooperative agreement for this activity and is midway through completion of this activity. This RFA will allow for completion of the activity.

C. Funding

Approximately $800,000 is available in FY 2005 to fund this award. It is expected that the award will begin on or before August 31, 2005, and will be made for a 12-month budget period within a project period of up to five years. Funding estimates may change.

D. Where To Obtain Additional Information

For general comments or questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone: 770–488–2700.

For program issues, contact: Trudy Messmer, Scientific Review Administrator, 1600 Clifton Road, MS C–19, Atlanta, GA 30333, Telephone: (404) 639–3770, E-mail: *TMessmer@cdc.gov.*

Dated: March 24, 2005.

William P. Nichols,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 05–6257 Filed 3–29–05; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Development of Influenza Surveillance Network in Vietnam; Notice of Intent To Fund Single Eligibility Award

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2005 funds for a cooperative agreement program to provide support and assistance to the government of Vietnam, specifically the National Institute of Hygiene and Epidemiology for the development and improvement of the influenza surveillance network in Vietnam. This network will focus on the systematic collection of virological and epidemiological information for influenza. The Catalog of Federal Domestic Assistance number for this program is 93.283.

B. Eligible Applicant

Assistance will be provided only to the Vietnam National Institute of Hygiene and Epidemiology through their Ministry of Health. Vietnam is being targeted for this cooperative agreement due to the recent outbreaks of highly pathogenic H5N1 avian influenza cases in humans and animals. The newly arising cases in humans are cause for great concern due to the potential of an influenza pandemic capable of causing millions of deaths. Since mid-December 2004, the Ministry of Health in Vietnam has confirmed 24 cases of human infection with H5N1 avian influenza. Of the 24 confirmed cases, 13 have resulted in fatalities. For the entire year of 2004, Vietnam had 28 human cases of H5N1 and 20 fatalities. Additionally, it appears that there are a growing number of possible family clusters suggesting the ability of the virus to spread through human to human contact. In response to these recent events in Vietnam, the Department of Health and Human Services requested that the Centers for Disease Control and Prevention create a cooperative agreement with Vietnam to enhance surveillance to address the current influenza situation as soon as possible. National Institute of Hygiene and Epidemiology (NIHE) has been chosen to conduct the surveillance for avian influenza because it serves as the National Influenza Center designated by the World Health Organization (WHO) and the Ministry of Health. As such, information collected by NIHE is reported directly into WHO's Global Influenza Surveillance System where it benefits countries globally.

C. Funding

Approximately $500,000 is available in FY 2005 to fund this award. It is expected that the award will begin on or before April 29, 2005 and will be made for a 12-month budget period within a project period of up to 5 years. Funding estimates may change.

D. Where To Obtain Additional Information

For general comments or questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone: 770–488–2700.

For technical questions about this program, contact: Ann Moen, Project Officer, CDC, National Center for Infectious Diseases, Mailstop G–16, 1600 Clifton Road, NE., Atlanta, GA 30333, Telephone: 404–639–4652, E-mail: *AMoen@cdc.gov.*

Dated: March 24, 2005.

William P. Nichols,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 05–6244 Filed 3–29–05; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2005N–0097]

Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Qualified Health Claims: Consumer Inferences About Omega-3 Fatty Acids and Monounsaturated Fatty Acids From Olive Oil

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a voluntary experimental study of consumer inferences about qualified health claims for omega-3 fatty acids and monounsaturated fatty acids from olive oil.

DATES: Submit written or electronic comments on the collection of information by May 31, 2005.

ADDRESSES: Submit electronic comments on the collection of information to: *http://www.fda.gov/dockets/ecomments*. Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Peggy Robbins, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Experimental Study of Qualified Health Claims: Consumer Inferences About Omega-3 Fatty Acids and Monounsaturated Fatty Acids From Olive Oil

FDA regulates the labeling of food products under the Nutrition Labeling and Education Act of 1990 (NLEA) and dietary supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA). NLEA regulations establish general requirements for health claims in food labeling. A manufacturer is required to provide a description of the scientific evidence supporting a proposed health claim to FDA for review and authorization before the claim may appear in labeling. NLEA health claims must be ''complete, truthful, and not misleading'' (§101.14(d)(iii) (21 CFR 101.14 (d)(iii)). NLEA also mandates that ''the claim enables the public to comprehend the information provided and to understand the relative significance of such information in the context of a total daily diet'' (§101.14 (d)(v)).

In 2003, an FDA Task Force on Consumer Health Information for Better Nutrition issued a report that provided guidance on an interim review process